Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0029005,
umls-concept:C0030705,
umls-concept:C0032854,
umls-concept:C0033325,
umls-concept:C0069515,
umls-concept:C0085862,
umls-concept:C0185117,
umls-concept:C0597879,
umls-concept:C0699791,
umls-concept:C1299583,
umls-concept:C1522602,
umls-concept:C1549571,
umls-concept:C1561558,
umls-concept:C1608386,
umls-concept:C1704824,
umls-concept:C2911684
|
pubmed:issue |
11
|
pubmed:dateCreated |
1991-6-12
|
pubmed:abstractText |
Correlations of c-erbB-2 protein expression with clinical outcomes of gastric carcinomas were studied in 189 gastric carcinomas. There were 23 (12.2%) carcinomas with evidence of c-erbB-2 protein in which the reaction was localized to the cell membrane. There was no significant association between c-erbB-2 staining and the macroscopic or histologic type of the carcinomas. c-erbB-2-stained tumors were more likely to be associated with serosal invasion, nodal involvement, and peritoneal metastasis, than c-erbB-2-unstained ones. In addition, c-erbB-2 was stained in none of early gastric carcinomas. The 5-year survival rates of the c-erbB-2 protein-positive and the protein-negative group were 11% and 50%, respectively. When the c-erbB-2 tissue status and seven clinicopathologic variables as conventional prognostic factors were entered simultaneously into the Cox regression model, serosal invasion, hepatic metastasis, peritoneal metastasis, nodal status, and c-erbB-2 tissue status emerged as independent prognostic variables. The results suggested that c-erbB-2 protein expression might be enhanced in advanced stages during the progression of gastric carcinoma. In this particular group of patients, immunoreactivity for c-erbB-2 protein is an indicator of poor short-term prognosis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0008-543X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
67
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
2914-8
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:1673870-Adult,
pubmed-meshheading:1673870-Aged,
pubmed-meshheading:1673870-Female,
pubmed-meshheading:1673870-Gene Amplification,
pubmed-meshheading:1673870-Humans,
pubmed-meshheading:1673870-Male,
pubmed-meshheading:1673870-Middle Aged,
pubmed-meshheading:1673870-Neoplasm Staging,
pubmed-meshheading:1673870-Prognosis,
pubmed-meshheading:1673870-Proto-Oncogene Proteins,
pubmed-meshheading:1673870-Receptor, erbB-2,
pubmed-meshheading:1673870-Stomach Neoplasms,
pubmed-meshheading:1673870-Tumor Markers, Biological
|
pubmed:year |
1991
|
pubmed:articleTitle |
Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma.
|
pubmed:affiliation |
Surgery II, School of Medicine, Kanazawa University, Japan.
|
pubmed:publicationType |
Journal Article
|